{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T11:33:26Z","timestamp":1791977606101,"version":"4.4.0"},"reference-count":14,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jiac-j.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection and Chemotherapy"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1016\/j.jiac.2017.08.005","type":"journal-article","created":{"date-parts":[[2017,10,13]],"date-time":"2017-10-13T13:45:56Z","timestamp":1507902356000},"page":"809-813","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Clinical pharmacokinetics and pharmacodynamic target attainment of pazufloxacin in prostate tissue: Dosing considerations for prostatitis"],"prefix":"10.1016","volume":"23","author":[{"given":"Kogenta","family":"Nakamura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuro","family":"Ikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Genya","family":"Nishikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ikuo","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Narushima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Muramatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shingo","family":"Morinaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keishi","family":"Kajikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiharu","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahito","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Zennami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kent","family":"Kanao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norifumi","family":"Morikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Sumitomo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jiac.2017.08.005_bib1","first-page":"412","article-title":"In\u00a0vitro and in\u00a0vivo antibacterial activities of pazufloxacin mesilate, a new injectable quinolone","volume":"55","author":"Nomura","year":"2002","journal-title":"Jpn J Antibiot"},{"key":"10.1016\/j.jiac.2017.08.005_bib2","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1254\/fpj.122.161","article-title":"Pharmacological properties and expected clinical role of an injectable new quinolone antibiotic, pazufloxacin mesilate","volume":"122","author":"Minami","year":"2003","journal-title":"Folia Pharmacol Jpn"},{"key":"10.1016\/j.jiac.2017.08.005_bib3","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1128\/AAC.39.9.2138","article-title":"Influence of a newly developed quinolone, T-3761, on pharmacokinetics of theophylline in rats","volume":"39","author":"Hasegawa","year":"1995","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2017.08.005_bib4","first-page":"287","article-title":"Pharmacokinetics and pharmacodynamic target attainment of intravenous pazufloxacin in the bile of patients undergoing biliary pancreatic surgery","volume":"26","author":"Uegami","year":"2014","journal-title":"J\u00a0Chemother"},{"key":"10.1016\/j.jiac.2017.08.005_bib5","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1128\/AAC.44.8.2046-2051.2000","article-title":"A\u00a0population pharmacokinetic analysis of the penetration of the prostate by levofloxacin","volume":"44","author":"Drusano","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2017.08.005_bib6","first-page":"32","article-title":"Determination of doripenem penetration into human prostate tissue and assessment of dosing regimens for prostatitis based on site-specific pharmacokinetic-pharmacodynamic evaluation","volume":"24","author":"Nakamura","year":"2012","journal-title":"J\u00a0Chemother"},{"key":"10.1016\/j.jiac.2017.08.005_bib7","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.ijantimicag.2012.11.001","article-title":"Prostatic penetration of meropenem in humans, and dosage considerations for prostatitis based on a site-specific pharmacokinetic\/pharmacodynamic evaluation","volume":"41","author":"Nishikawa","year":"2013","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jiac.2017.08.005_bib8","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.jiac.2015.04.015","article-title":"Penetration of piperacillin-tazobactam into human prostate tissue and dosing considerations for prostatitis based on site-specific pharmacokinetics and pharmacodynamics","volume":"21","author":"Kobayashi","year":"2015","journal-title":"J\u00a0Infect Chemother"},{"key":"10.1016\/j.jiac.2017.08.005_bib9","doi-asserted-by":"crossref","first-page":"S127","DOI":"10.1086\/428053","article-title":"Clinical implications of pharmacokinetics and pharmacodynamics of fluoroquinolones","volume":"41","author":"Wispelwey","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jiac.2017.08.005_bib10","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1097\/01.CCM.0000150265.42067.4C","article-title":"Pharmacokinetics and intrapulmonary diffusion of levofloxacin in critically ill patients with severe community-acquired pneumonia","volume":"33","author":"Boselli","year":"2005","journal-title":"Crit Care Med"},{"key":"10.1016\/j.jiac.2017.08.005_bib11","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1086\/510079","article-title":"Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it's not just for mice anymore","volume":"44","author":"Ambrose","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jiac.2017.08.005_bib12","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.ijantimicag.2007.02.006","article-title":"Evaluation of gatifloxacin pharmacokinetics and pharmacodynamics in severely ill adults in a medical intensive care unit","volume":"29","author":"Fish","year":"2007","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jiac.2017.08.005_bib13","series-title":"43rd interscience conference on antimicrobial agents and chemotherapy (ICAAC)","article-title":"Evaluation of pharmacodynamic target attainment between healthy subject and patients' data using Monte Carlo simulation","author":"Kuti","year":"2003"},{"key":"10.1016\/j.jiac.2017.08.005_bib14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijantimicag.2005.04.013","article-title":"The role of antibiotics in chronic bacterial prostatitis","volume":"26","author":"Wagenlehner","year":"2005","journal-title":"Int J Antimicrob Agents"}],"container-title":["Journal of Infection and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X17301848?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X17301848?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T18:56:27Z","timestamp":1761159387000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1341321X17301848"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":14,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["S1341321X17301848"],"URL":"https:\/\/doi.org\/10.1016\/j.jiac.2017.08.005","relation":{},"ISSN":["1341-321X"],"issn-type":[{"value":"1341-321X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical pharmacokinetics and pharmacodynamic target attainment of pazufloxacin in prostate tissue: Dosing considerations for prostatitis","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection and Chemotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jiac.2017.08.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}